Clinical trial design for microarray predictive marker discovery and assessment von Pusztai, L., Hess, K. R.

Volltext

Utility of Histologic and Radiologic Response to Induction Chemotherapy in Patients With Ewing Sarcoma (EWS) von Pan, H, Morani, A, Wang, W, Hess, K.R, Lin, P.P, Daw, N.C, Mahajan, A

Volltext

Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers von Mazouni, C, Kau, S-W, Frye, D, Andre, F, Kuerer, HM, Buchholz, TA, Symmans, WF, Anderson, K, Hess, KR, Gonzalez-Angulo, AM, Hortobagyi, GN, Buzdar, AU, Pusztai, L

Volltext

The Role of Ultrasound of the Regional Nodal Basins in Staging Patients With Triple-Negative Breast Cancer: Implications for Local-Regional Treatment von Shaitelman, S.F, Tereffe, W, Hess, K.R, Gonzalez Angulo, A.M, Dogan, B.E, Stauder, M.C, Valero, V, Krishnamurthy, S, Strom, E.A, Hunt, K.K, Buchholz, T.A, Whitman, G.J

Volltext

5177 POSTER Correlation Between PARP-1 Expression and ln-vitro Chemotherapy Sensitivity in Patients With Breast Cancer von Liedtke, C, Packeisen, J, Denkert, C, Gluz, O, Tio, J, Kiesel, L, Vogt, U, Müller, B, Hess, K.R, Bürger, H

Volltext

Statistical model to predict brain metastasis risk in patients with early-stage breast cancer von Abderrahman, B., Ibrahim, N.K., Hess, K.R.

Volltext

The prognostic impact of age in patients with triple-negative breast cancer von Liedtke, Cornelia, Hess, K. R., Karn, T., Rody, A., Kiesel, L., Hortobagyi, G. N., Pusztai, L., Gonzalez-Angulo, A. M.

Volltext

10P Prediction of the 21-gene recurrence score by a non-genomic approach in stage I estrogen receptor-positive, HER2-negative breast cancer von Le Du, F., Takeo, F., Park, M., Hess, K.R., Liu, D., Jackson, R., Mylander, C., Rosman, M., Raghavendra, A., Tafra, L., Ueno, N.T.

Volltext

Postoperative MRI Evaluation of a Radiofrequency Cordotomy Lesion for Intractable Cancer Pain von Vedantam, A, Hou, P, Chi, T L, Hess, K R, Dougherty, P M, Bruera, E, Viswanathan, A

Volltext

Prognostic implications of circulating tumor cells (CTCs) after neoadjuvant chemotherapy for triple negative breast cancer (TNBC) von Hall, C., Hess, K.R., Ravenberg, L., Clayborn, A., Rauch, G.M., Candelaria, R., Mittendorf, E.A., Moulder, S.L., Thompson, A., Lucci, A.

Volltext

A pilot study of neoadjuvant talazoparib for early-stage breast cancer patients with a BRCA mutation von Litton, J.K., Scoggins, M., Ramirez, D.L., Murthy, R.K., Whitman, G.J., Hess, K.R., Adrada, B.E., Moulder, S.L., Barcenas, C.H., Valero, V., Booser, D., Gomez, J. Schwartz, Mills, G.B., Piwnica-Worms, H., Arun, B.K.

Volltext

Pembrolizumab in advanced rare cancers von Naing, A., Meric-Bernstam, F., Karp, D., Rodon, J.A., Piha-Paul, S.A., Subbiah, V., Hong, D.S., Pant, S., Fu, S., Janku, F., Yap, T.A., Tsimberidou, A.M., Dumbrava, E E Ileana, Colen, R.R., Hess, K.R., Campbell, M.T., Tu, S.-M., Jimenez, C., Habra, M.A., Varadhachary, G.R.

Volltext

1270P - Pembrolizumab in advanced rare cancers von Naing, A., Meric-Bernstam, F., Karp, D., Rodon, J.A., Piha-Paul, S.A., Subbiah, V., Hong, D.S., Pant, S., Fu, S., Janku, F., Yap, T.A., Tsimberidou, A.M., Dumbrava, E E Ileana, Colen, R.R., Hess, K.R., Campbell, M.T., Tu, S.-M., Jimenez, C., Habra, M.A., Varadhachary, G.R.

Volltext

Neoadjuvant trial of nab-paclitaxel and atezolizumab (Atezo), a PD-L1 inhibitor, in patients (pts) with chemo-insensitive triple negative breast cancer (TNBC) von Litton, J.K., Moulder, S.L., Hess, K.R., Damodaran, S., Rauch, G.M., Candelaria, R., Adrada, B.E., Symmans, F., Murthy, R.K., Helgason, T., Clayborn, A., Prabhakaran, S., Valero, V., Thompson, A.M., Mittendorf, E.A.

Volltext

Ki67 expression in the primary tumor predicts for clinical benefit and time to progression on first-line endocrine therapy in estrogen receptor-positive metastatic breast cancer von Delpech, Y., Wu, Y., Hess, K. R., Hsu, L., Ayers, M., Natowicz, R., Coutant, C., Rouzier, R., Barranger, E., Hortobagyi, G. N., Mauro, D., Pusztai, L.

Volltext

Impact of clinical, morphologic and molecular characteristics on response to neoadjuvant systemic therapy (NAST) in metaplastic breast cancer (MpBC) von Yam, C., Seth, S., Hess, K.R., Mittendorf, E.A., Murthy, R.K., Damodaran, S., Helgason, T., Huo, L., Thompson, A.M., Barton, M., Huang, M.L., Arribas, E.M., Lane, D.L., Rauch, G.M., Adrada, B.E., Gilcrease, M.Z., Chang, J.T., Moulder, S.L.

Volltext

Improving outcomes in triple-negative breast cancer (TNBC) using molecular characterization and diagnostic imaging to identify and treat chemo-insensitive disease von Moulder, S.L., Litton, J.K., Mittendorf, E., Yang, W., Ueno, N., Hess, K.R., Valero, V., Murthy, R.K., Ibrahim, N., Lim, B., Arun, B.K., Thompson, A., Piwnica-Worms, H., Tripathy, D., Symmans, W.F.

Volltext

Autophagy-inducing agents augment the antitumor effect of telomerase-selective oncolytic adenovirus OBP-405 on glioblastoma cells von YOKOYAMA, T, IWADO, E, HASHIMOTO, Y, URATA, Y, FUJIWARA, T, KONDO, S, KONDO, Y, AOKI, H, HAYASHI, Y, GEORGESCU, M. M, SAWAYA, R, HESS, K. R, MILLS, G. B, KAWAMURA, H

Volltext

Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors: a phase I study von Cascone, T., Sacks, R.L., Subbiah, I.M., Drobnitzky, N., Piha-Paul, S.A., Hong, D.S., Hess, K.R., Amini, B., Bhatt, T., Fu, S., Naing, A., Janku, F., Karp, D., Falchook, G.S., Conley, A.P., Sherman, S.I., Meric-Bernstam, F., Ryan, A.J., Heymach, J.V., Subbiah, V.

Volltext

The prognostic significance of left ventricular ejection fraction in patients with advanced cancer treated in phase I clinical trials von Said, R., Banchs, J., Wheler, J., Hess, K.R., Falchook, G., Fu, S., Naing, A., Hong, D., Piha-Paul, S., Ye, Y., Yeh, E., Wolff, R.A., Tsimberidou, A.M.

Volltext